Literature DB >> 15080767

Treatment of juvenile Graves' disease and its ophthalmic complication: the 'European way'.

G E Krassas1.   

Abstract

Three treatment modalities are available for Graves' disease: antithyroid drugs, surgery and radioactive iodine (RAI). None has been shown to be ideal or superior to the others. There are wide differences between individual physicians and between the physicians in different countries on the optional treatment for childhood hyperthyroidism. While antithyroid drugs remain the initial treatment of choice in almost all the medical centers in Europe, with surgery being used mainly to deal with antithyroid failures, radioiodine is preferred by only a small percentage of physicians for this group of patients. In the USA, on the contrary, radioiodine treatment of thyrotoxicosis in children has strong advocates, who emphasize the safety, simplicity and economic advantages of iodine-131 ablation, which should be considered more commonly in children. Until now, the available data have shown no significant increase in thyroid neoplasia, gonadal injury or congenital abnormalities in the offspring of older children and adults receiving RAI for thyrotoxicosis. Given the considerable increase in the risk of thyroid cancer in young children exposed to external radiation, it has been hypothesized that there may be a small increase in the risk of thyroid cancer in young children treated with RAI. Until long-term data on safety are available, specifically for young children, differences between the physicians in different countries will remain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15080767     DOI: 10.1530/eje.0.1500407

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  ANCA-associated diffuse alveolar hemorrhage due to benzylthiouracil.

Authors:  Farah Thabet; Rim Sghiri; Brahim Tabarki; Ibtissem Ghedira; Moncef Yacoub; Ahmed Sahloul Essoussi
Journal:  Eur J Pediatr       Date:  2006-04-19       Impact factor: 3.183

2.  Childhood Graves' disease and its ophthalmic complications: some sensitive issues.

Authors:  G E Krassas
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

3.  Clinical features of pediatric Graves' orbitopathy.

Authors:  J Eha; S Pitz; J Pohlenz
Journal:  Int Ophthalmol       Date:  2010-02-27       Impact factor: 2.031

Review 4.  Surgical treatment of Graves' disease: evidence-based approach.

Authors:  Peter Stålberg; Anna Svensson; Ola Hessman; Göran Akerström; Per Hellman
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

5.  Association between polymorphisms in the TSHR gene and Graves' orbitopathy.

Authors:  Beata Jurecka-Lubieniecka; Rafal Ploski; Dorota Kula; Konrad Szymanski; Tomasz Bednarczuk; Urszula Ambroziak; Kornelia Hasse-Lazar; Lidia Hyla-Klekot; Andrzej Tukiendorf; Zofia Kolosza; Barbara Jarzab
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.